(Stockholm, 4 May, 2020) Inhalation Sciences (ISAB) has signed a CRO (Contract Research) order worth over 30 KEUR with a global pharmaceutical company. CEO Manoush Masarrat: "The demand for ISAB's technology remains despite current challenges and restrictions related to Covid-19. With so much urgent research in the respiratory field ongoing right now, our in-house research is crucial. This order shows that the data our in vitro lung simulation tool DissolvIt[® ]deliver are, quite simply, leading."
The Contract Research will use ISAB's in vitro simulation tool DissolvIt[®]. A leading in vitro solution within inhalation research. DissolvIt[® ]is in high demand, 3 earlier orders of the module were shipped to customers after its commercial launch in Q1 2020.
The total value of the order with Teva Pharmaceuticals is 44 KEUR. 30.5 KEUR will be for services provided by ISAB. The remaining 13.5 KEUR will go to another research company collaborating on the project.
ISAB CEO Manoush Masarrat "This order shows how crucial our CRO capabilities are. Not only do they build vital bridges with new customers, educating and demonstrating the outstanding capabilities of our technology-but with today's travel restrictions, CRO is a high-value way to keep providing our customers with the leading data they need, and that today's challenging situation so urgently requires."
ISAB Director of Projects and in vitro specialist Maria Malmlöf: "The IVIVC (In Vitro In Vivo Correlation) capabilities of DissolvIt are leading, generating vital data, including Cmax and Tmax curves, that until now have not been able to be captured using conventional in vitro experiments. We're looking forward to getting down to work."